Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice

Psychopharmacology

Volumn 215, Issue 3, 2011, Pages 581-593

  Dougherty, John P ^a   Aloyo, Vincent J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

5 HT2A receptor; 5 HT2C receptor; Affinity; Cortex; Frontal cortex; Mouse; Pharmacological profile; Rat; Receptor density; Receptor regulation

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; GLEMANSERIN; KETANSERIN; MESULERGINE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SODIUM CHLORIDE; TRITIUM; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; ALPHA-PHENYL-1-(2-PHENYLETHYL)-4-PIPERIDINEMETHANOL; AMPHETAMINE DERIVATIVE; LIGAND; PIPERIDINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BRAIN CORTEX; CONTROLLED STUDY; CORRELATION ANALYSIS; FRONTAL CORTEX; HEAD TWITCH; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; RECEPTOR DENSITY; SPECIES DIFFERENCE; ANIMAL; C57BL MOUSE; DRUG EFFECT; HUMAN; METABOLISM; PROTEIN BINDING; SPRAGUE DAWLEY RAT;

AMPHETAMINES; ANIMALS; CEREBRAL CORTEX; HUMANS; LIGANDS; MALE; MICE; MICE, INBRED C57BL; PIPERIDINES; PROTEIN BINDING; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; SPECIES SPECIFICITY;

EID: 80052306107     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2207-6     Document Type: Article

References (75)

1. Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21(2 Suppl): 16S-23S (Pubitemid 29396466)
2. Aloyo VJ, Harvey JA (2000) Antagonist binding at 5-HT(2A) and 5-HT (2C) receptors in the rabbit: high correlation with the profile for the human receptors. Eur J Pharmacol 406(2): 163-169
3. Aloyo VJ, Dave KD, Rahman T, Harvey JA (2001) Selective and divergent regulation of cortical 5-HT(2A) receptors in rabbit. J Pharmacol Exp Ther 299(3): 1066-1072 (Pubitemid 33107373)
4. Aloyo VJ, Berg KA, Spampinato U, Clarke WP, Harvey JA (2009) Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. Pharmacol Ther 121(2): 160-173
5. Anji A, Kumari M, Sullivan Hanley NR, Bryan GL, Hensler JG (2000) Regulation of 5-HT(2A) receptor mRNA levels and binding sites in rat frontal cortex by the agonist DOI and the antagonist mianserin. Neuropharmacology 39(11): 1996-2005 (Pubitemid 30645623)
6. Battaglia G, Shannon M, Borgundvaag B, Titeler M (1983) pHdependent modulation of agonist interactions with [3H]-ketanserin-labelled S2 serotonin receptors. Life Sci 33 (20): 2011-2016 (Pubitemid 13021863)
7. Battaglia G, Shannon M, Titeler M (1984) Guanyl nucleotide and divalent cation regulation of cortical S2 serotonin receptors. J Neurochem 43(5): 1213-1219 (Pubitemid 15206964)
8. Berg KA, Harvey JA, Spampinato U, Clarke WP (2008) Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression. Prog Brain Res 172: 287-305
9. Blackshear MA, Sanders-Bush E (1982) Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exp Ther 221(2): 303-308 (Pubitemid 12122941)
10. Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, Eglen RM (1995) The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol 115(4): 622-628
11. Braden MR, Nichols DE (2007) Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol Pharmacol 72(5): 1200-1209 (Pubitemid 350012594)
12. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
13. Canal CE, Olaghere da Silva UB, Gresch PJ, Watt EE, Sanders-Bush E, Airey DC (2010) The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology (Berl) 209 (2): 163-174
14. Chaouloff F, Baudrie V, Coupry I (1993) Behavioural and biochemical evidence that glucocorticoids are not involved in DOI-elicited 5-HT2 receptor down-regulation. Eur J Pharmacol 249(1): 117-120 (Pubitemid 23326918)
15. Chaouloff F, Kulikov A, Mormède P (1997) Repeated DOI and SR 46349B treatments do not affect elevated plus-maze anxiety despite opposite effects on cortical 5-HT2A receptors. Eur J Pharmacol 334(1): 25-29 (Pubitemid 27417804)
16. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22(23): 3099-3108
17. Darmani NA, Martin BR, Glennon RA (1990) Withdrawal from chronic treatment with (+/-)-DOI causes super-sensitivity to 5-HT2 receptor-induced head-twitch behaviour in mice. Eur J Pharmacol 186(1): 115-118 (Pubitemid 20277552)
18. Dave KD, Harvey JA, Aloyo VJ (2007) The time-course for up-and down-regulation of the cortical 5-hydroxytryptamine (5-HT)2A receptor density predicts 5-HT2A receptor-mediated behavior in the rabbit. J Pharmacol Exp Ther 323(1): 327-335 (Pubitemid 47443241)
19. Dursun SM, Handley SL (1996) Similarities in the pharmacology of spontaneous and DOI-induced head-shakes suggest 5HT2A receptors are active under physiological conditions. Psychopharmacology (Berl) 128(2): 198-205 (Pubitemid 26383307)
20. El Mansari M, Blier P (2006) Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30(3): 362-373 (Pubitemid 43841738)
21. Fone KC, Austin RH, Topham IA, Kennett GA, Punhani T (1998) Effect of chronic m-CPP on locomotion, hypophagia, plasma corticosterone and 5-HT2C receptor levels in the rat. Br J Pharmacol 123(8): 1707-1715 (Pubitemid 28182055)
22. Fox MA, French HT, Laporte JL, Blackler AR, Murphy DL (2010) The serotonin 5-HT(2A) receptor agonist TCB-2: a behavioral and neurophysiological analysis. Psychopharmacology 212(1): 13-23
23. González-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, Weisstaub N, Hen R, Gingrich JA, Sealfon SC (2003) Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23(26): 8836-8843 (Pubitemid 37210895)
24. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53(3): 439-452 (Pubitemid 46161267)
25. Goodwin GM, Green AR, Johnson P (1984) 5-HT2 receptor characteristics in frontal cortex and 5-HT2 receptor-mediated head-twitch behaviour following antidepressant treatment to mice. Br J Pharmacol 83(1): 235-242 (Pubitemid 14028836)
26. Gray JA, Roth BL (2001) Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56 (5): 441-451 (Pubitemid 34031779)
27. Hagen JD, Pierce PA, Peroutka SJ (1994) Differential binding of ergot compounds to human versus rat 5-HT2 cortical receptors. Biol Signals 3(5): 223-229
28. Harvey JA (2003) Role of the serotonin 5-HT(2A) receptor in learning. Learn Mem 10(5): 355-362 (Pubitemid 37266680)
29. Hayslett RL, Tizabi Y (2005) Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette's syndrome. Pharmacol Biochem Behav 81 (4): 879-886 (Pubitemid 41187823)
30. Heal DJ, Philpot J, Molyneux SG, Metz A (1985) Intracerebroventricular administration of 5, 7-dihydroxytryptamine to mice increases both head-twitch response and the number of cortical 5-HT2 receptors. Neuropharmacology 24(12): 1201-1205 (Pubitemid 16182645)
31. Hensler JG, Truett KA (1998) Effect of chronic serotonin-2 receptor agonist or antagonist administration on serotonin-1A receptor sensitivity. Neuropsychopharmacology 19(5): 354-364 (Pubitemid 28451592)
32. Hoyer D, Engel G, Kalkman HO (1985) Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. Eur J Pharmacol 118(1-2): 13-23 (Pubitemid 16189567)
33. Hoyer D, Pazos A, Probst A, Palacios JM (1986) Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res 376(1): 97-107 (Pubitemid 16046020)
34. Hulihan-Giblin BA, Park YD, Aulakh CS (1994) Differential effects of chronic antidepressant treatment on 5-HT1C receptor binding sites in Wistar rat brain. Eur J Pharmacol 263(1-2): 213-216 (Pubitemid 24290275)
35. Johnson MP, Loncharich RJ, Baez M, Nelson DL (1994) Species variations in transmembrane region Vof the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol 45(2): 277-286 (Pubitemid 24063081)
36. Johnson MP, Siegel BW, Carr AA (1996) [3H]MDL 100, 907: a novel selective 5-HT2A receptor ligand. Naunyn Schmiedebergs Arch Pharmacol 354(2): 205-209 (Pubitemid 26248261)
37. Johnson MP, Wainscott DB, Lucaites VL, Baez M, Nelson DL (1997) Mutations of transmembrane IV and V serines indicate that all tryptamines do not bind to the rat 5-HT2A receptor in the same manner. Brain Res Mol Brain Res 49(1-2): 1-6 (Pubitemid 27453108)
38. Kao HT, Adham N, Olsen MA, Weinshank RL, Branchek TA, Hartig PR (1992) Site-directed mutagenesis of a single residue changes the binding properties of the serotonin 5-HT2 receptor from a human to a rat pharmacology. FEBS Lett 307(3): 324-328
39. Leonhardt S, Gorospe E, Hoffman BJ, Teitler M (1992) Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. Mol Pharmacol 42(2): 328-335 (Pubitemid 23026167)
40. Leysen JE, Janssen PF, Niemegeers CJ (1989) Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment. Eur J Pharmacol 163(1): 145-149 (Pubitemid 19107556)
41. Leysen JE, Niemegeers CJ, Van Nueten JM, Laduron PM (1982) [3H] Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 21(2): 301-314 (Pubitemid 12139828)
42. Leysen JE, Eens A, Gommeren W, van Gompel P, Wynants J, Janssen PA (1988) Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin-and tetrabenazine-like drugs. J Pharmacol Exp Ther 244(1): 310-321 (Pubitemid 18042398)
43. Leysen JE, Pauwels PJ (1990) 5-HT2 receptors, roles and regulation. Ann NY Acad Sci 600: 183-191, discussion 192-193
44. López-Giménez JF, Vilaró MT, Palacios JM, Mengod G (1998) [3H] MDL 100, 907 labels 5-HT2A serotonin receptors selectively in primate brain. Neuropharmacology 37(9): 1147-1158 (Pubitemid 29027829)
45. López-Giménez JF, Tecott LH, Palacios JM, Mengod G, Vilaró MT (2002) Serotonin 5-HT (2C) receptor knockout mice: autoradiographic analysis of multiple serotonin receptors. J Neurosci Res 67(1): 69-85
46. Lyon RA, Davis KH, Titeler M (1987) 3H-DOB (4-bromo-2, 5-dimethoxyphenylisopropylamine) labels a guanyl nucleotidesensitive state of cortical 5-HT2 receptors. Mol Pharmacol 31 (2): 194-199 (Pubitemid 17038899)
47. Marek GJ, Carpenter LL, McDougle CJ, Price LH (2003) Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28(2): 402-412
48. McKenna DJ, Peroutka SJ (1989) Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2, 5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin. J Neurosci 9(10): 3482-3490 (Pubitemid 19260020)
49. McPherson GA (1985) Kinetic, ebda, ligand, lowry: a collection of radioligand binding analysis programmes. Biosoft, Cambridge, MA
50. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251(1): 238-246
51. Metz A, Heal DJ (1986) In mice repeated administration of electroconvulsive shock or desmethylimipramine produces rapid alterations in 5-HT2-mediated head-twitch responses and cortical 5-HT2 receptor number. Eur J Pharmacol 126(1-2): 159-162 (Pubitemid 16014748)
52. Michelsen KA, Prickaerts J, Steinbusch HWM (2008) The dorsal raphe nucleus and serotonin: implications for neuroplasticity linked to major depression and Alzheimer's disease. Prog Brain Res 172: 233-264
53. Neale RF, Fallon SL, Boyar WC, Wasley JW, Martin LL, Stone GA, Glaeser BS, Sinton CM, Williams M (1987) Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. Eur J Pharmacol 136(1): 1-9 (Pubitemid 17109585)
54. Nelson DL, Lucaites VL, Audia JE, Nissen JS, Wainscott DB (1993) Species differences in the pharmacology of the 5-hydroxytryptamine2 receptor: structurally specific differentiation by ergolines and tryptamines. J Pharmacol Exp Ther 265 (3): 1272-1279 (Pubitemid 23321030)
55. Pazos A, Hoyer D, Palacios JM (1984) Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine and human cortex: evidence for species differences in brain serotonin-2 receptors. Eur J Pharmacol 106(3): 531-538 (Pubitemid 15194102)
56. Pazos A, Cortés R, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346(2): 231-249 (Pubitemid 16241112)
57. Pazos A, Probst A, Palacios JM (1987) Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21(1): 123-139
58. Peroutka SJ, Lebovitz RM, Snyder SH (1981) Two distinct central serotonin receptors with different physiological functions. Science 212(4496): 827-829 (Pubitemid 11069388)
59. Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23 (1-2): 163-178
60. Pranzatelli MR, Balletti J (1992) Serotonin receptors in human neuroblastoma: a possible biologic tumor marker. Exp Neurol 115(3): 423-427
61. Richtand NM, Welge JA, Logue AD, Keck PE, Strakowski SM, McNamara RK (2008) Role of serotonin and dopamine receptor binding in antipsychotic efficacy. Prog Brain Res 172: 155-175
62. Rinaldi-Carmona M, Congy C, Santucci V, Simiand J, Gautret B, Neliat G, Labeeuw B, Le Fur G, Soubrie P, Breliere JC (1992) Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. J Pharmacol Exp Ther 262(2): 759-768
63. Rinaldi-Carmona M, Congy C, Simiand J, Oury-Donat F, Soubrie P, Breliere JC, Le Fur G (1993a) Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, upregulates 5-hydroxytryptamine2 receptors in mouse brain. Mol Pharmacol 43(1): 84-89 (Pubitemid 23027653)
64. Rinaldi-Carmona M, Bouaboula M, Congy C, Oury-Donat F, Simiand J, Shire D, Casellas P, Soubrié P, Brelière JC, Le Fur G (1993b) Up-regulation of 5-HT2 receptors in the rat brain by repeated administration of SR 46349B, a selective 5-HT2 receptor antagonist. Eur J Pharmacol 246(1): 73-80 (Pubitemid 23178336)
65. Rioux A, Fabre V, Lesch KP, Moessner R, Murphy DL, Lanfumey L, Hamon M, Martres MP (1999) Adaptive changes of serotonin 5-HT2A receptors in mice lacking the serotonin transporter. Neurosci Lett 262(2): 113-116 (Pubitemid 29130301)
66. Roth BL, Ciaranello RD, Meltzer HY (1992) Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260(3): 1361-1365
67. Sadzot B, Baraban JM, Glennon RA, Lyon RA, Leonhardt S, Jan CR, Titeler M (1989) Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology (Berl) 98(4): 495-499 (Pubitemid 19193897)
68. Schotte A, Maloteaux JM, Laduron PM (1983) Characterization and regional distribution of serotonin S2-receptors in human brain. Brain Res 276(2): 231-235 (Pubitemid 13009710)
69. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995) (1-(2, 5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273 (1): 101-112
70. Smith RL, Barrett RJ, Sanders-Bush E (1999) Mechanism of tolerance development to 2, 5-dimethoxy-4-iodoamphetamine in rats: down-regulation of the 5-HT2A, but not 5-HT2C, receptor. Psychopharmacology (Berl) 144(3): 248-254 (Pubitemid 29307276)
71. Steeves TDL, Fox SH (2008) Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome. Prog Brain Res 172: 495-513
72. Van Oekelen D, Luyten WHML, Leysen JE (2003) 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 72(22): 2429-2449 (Pubitemid 36321816)
73. Wainscott DB, Lucaites VL, Kursar JD, Baez M, Nelson DL (1996) Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. J Pharmacol Exp Ther 276 (2): 720-727
74. Weber JT, O'Connor MF, Hayataka K, Colson N, Medora R, Russo EB, Parker KK (1997) Activity of parthenolide at 5HT2A receptors. J Nat Prod 60(6): 651-653
75. Weiss KC, Kim DY, Pawson CT, Cordes SP (2003) A genetic screen for mouse mutations with defects in serotonin responsiveness. Brain Res Mol Brain Res 115(2): 162-172 (Pubitemid 36859866)